HALISTER: Lilly FY Adj. EPS Forecast Midpoint Matches Est.

Lilly FY Adj. EPS Forecast Midpoint Matches Est.

(Bloomberg) -- Lilly sees FY adj. EPS $4.05 to $4.15, est. $4.10
  • Sees FY rev. $21.8b to $22.3b, est. $22.0b
  • 4Q adj. EPS 95c, est. 98c (range 87c-$1.03)
  • 4Q rev. $5.76b, est. $5.54b (range $5.35b-$5.73b)
  • 4Q Humalog rev. $819.8m, est. $757.9m (Bloomberg data)
    • 4Q Cialis rev. $676.3m, est. $633.3m
    • 4Q Alimta rev. $541.6m, est. $543.4m
    • 4Q Forteo rev. $422.5m, est. $395.0m (average of 7)
    • 4Q Trulicity rev. $337.0m, est. $286.5m
    • 4Q Cyramza rev. $177.1m, est. $168.7m (average of 6)
    • 4Q Taltz rev. $61.3m, est. $61.2m (average of 5)
    • 4Q Cymbalta rev. $181.8m, est. $167.4m (average of 7)
    • 4Q Zyprexa rev. $153.0m, est. $151.7m (average of 7)
  • 4Q gross margin 74.6%
  • 4Q Jardiance rev. $76.1m
  • 4Q Basaglar rev. $39.5m
NOTE:
  • 20 buys, 5 holds, 0 sells before today
  • Call 11:30am (NY time), (612)-234-9960 pw 414401
Statement
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
LLY US (Eli Lilly & Co)
4507 JP (Shionogi & Co Ltd)

To de-activate this alert, click here

UUID: 7947283